Although some systemic toxicity was observed with the combined use of VS4718 and trametinib, the observed synergy suggests dose-sparing potential, supporting the combined targeting of MEK and FAK in GBM as a valid therapeutic approach. Here, MAP2K7 is linked to glioblastoma.